Letter by Rosenstein and Parra Regarding Article, “Greater Clinical Benefit of More Intensive Oral Antiplatelet Therapy With Prasugrel in Patients With Diabetes Mellitus in the Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition With Prasugrel: Thrombolysis in Myocardial Infarction 38”
Details
The content you want is available to Zendy users.Already have an account? Click here. to sign in.